Back

Beta-blockers in hypertensive patients with comorbidities: where do we stand?

2 September 2019 (10:15 - 10:27)
Organised by:
Congress Presentation Part of: Combinations of beta-blockers and angiotensin-converting enzyme inhibitors: what is the rationale? Treatment ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Christoph Maack

University Clinic Wuerzburg, Wuerzburg (Germany)

2 More presentations in this session

Presentation thumbnail
Combinations of beta-blockers and angiotensin-converting enzyme inhibitors: Why, when and for whom are they in line with the guidelines?
Doctor J. Wolf (Gdansk, PL)
Slides Video
Presentation thumbnail
Discussion
Professor C. Maack (Wuerzburg, DE) Professor K. Tsioufis (Athens, GR) Doctor J. Wolf (Gdansk, PL)
Slides Video

Access the full session

Session thumbnail
Combinations of beta-blockers and angiotensin-converting enzyme inhibitors: what is the rationale?

The Event

Event poster

ESC Congress 2019

2 September 2019 10:15 CET
You may be interested in
thumbnail
Congress Session
Challenges in hypertension management
26 August 2023
thumbnail
Webinar
Are beta-blockers still indicated after myocardial infarction?
17 November 2025
thumbnail
Congress Presentation
Effectiveness of bisoprolol versus selective beta-1 blockers in the management of hypertension: a systematic review and meta-analysis of randomized cross-over trials
27 August 2021
thumbnail
Congress Presentation
Association between comorbidities and blood pressure trajectories in patients with hypertension
1 September 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources